Istacare 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Istacare 50/500 is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults inadequately controlled on metformin alone or in combination with other antidiabetic agents. It is important to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with metformin. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Dose adjustments may be necessary in patients with renal impairment. Istacare 50/500 should be used under medical supervision with regular monitoring of blood glucose and HbA1c levels to optimize therapeutic outcomes.